ACKNOWLEDGEMENT
Medical writing and editorial support were provided by Mark
Skopin and Paul Ferguson of Prescott Medical Communications
Group (Chicago, IL) with financial support from Ortho Dermatologics.
Ortho Dermatologics is a division of Bausch Health US,
LLC.
REFERENCES
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496- 509.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
3. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1-18.
4. Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358-365.
5. Armstrong AW, Villanueva Quintero DG, Echeverria CM, et al. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a randomized controlled trial of adalimumab. Am J Clin Dermatol. 2016;17(6):691-699.
6. Blauvelt A, Muram TM, See K, et al. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatolog Treat. 2018;29(3):220-229.
7. Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332- 337.
8. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148-1158.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
10. Stein Gold L, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-tosevere plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287-293.
11. Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate- to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17(8):855-861. 12. Mueller SM, Tomaschett D, Vogt DR, et al. Topical corticosteroid concerns from the clinicians' perspective. J Dermatolog Treat. 2017;28(5):464-468.
13. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019:1-8.
2. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. Lancet. 2007;370(9583):263-271.
3. Farber EM, Nall ML. The natural history of psoriasis in 5,600 patients. Dermatologica. 1974;148(1):1-18.
4. Augustin M, Sommer R, Kirsten N, et al. Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. Br J Dermatol. 2019;181(2):358-365.
5. Armstrong AW, Villanueva Quintero DG, Echeverria CM, et al. Body Region Involvement and Quality of Life in Psoriasis: Analysis of a randomized controlled trial of adalimumab. Am J Clin Dermatol. 2016;17(6):691-699.
6. Blauvelt A, Muram TM, See K, et al. Improvements in psoriasis within different body regions vary over time following treatment with ixekizumab. J Dermatolog Treat. 2018;29(3):220-229.
7. Hjuler KF, Iversen L, Rasmussen MK, et al. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181(2):332- 337.
8. Menter A, Papp KA, Gooderham M, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30(7):1148-1158.
9. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60(4):643-659.
10. Stein Gold L, Lebwohl MG, Sugarman JL, et al. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-tosevere plaque psoriasis: Results of 2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2018;79(2):287-293.
11. Sugarman JL, Weiss J, Tanghetti EA, et al. Safety and efficacy of a fixed combination halobetasol and tazarotene lotion in the treatment of moderate- to-severe plaque psoriasis: a pooled analysis of two phase 3 studies. J Drugs Dermatol. 2018;17(8):855-861. 12. Mueller SM, Tomaschett D, Vogt DR, et al. Topical corticosteroid concerns from the clinicians' perspective. J Dermatolog Treat. 2017;28(5):464-468.
13. Tanghetti EA, Stein Gold L, Del Rosso JQ, et al. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology. J Dermatolog Treat. 2019:1-8.
AUTHOR CORRESPONDENCE
Stephen Tyring MD PhD styring@ccstexas.com
